| |
|
|
|
Xtalks, Online
2025-11-14
Traditional discovery approaches force a trade-off: deep biological resolution for a few perturbations or broad screens with limited endpoints. This webinar explores how a high-throughput transcriptomics assay addresses this challenge by enabling genome-wide expression profiling at an industrial scale, supporting the discovery of mechanisms of action, pathway analysis and therapeutic safety assessment.
Attendees will explore how broad compound profiling in primary human cells supports clustering by mechanism, uncovers shared and divergent regulatory programs and enables data-rich screening. The session will also examine how transcriptomic responses to perturbations can reveal off-target effects in RNAi therapeutics, moving beyond simple knockdown measurements.
The featured speakers will highlight how high-resolution transcriptomic data improves model building, predictive toxicology and large-scale screening, providing both breadth and depth in early-stage research.
Register for this webinar to learn how transcriptomics assays are transforming data-driven drug discovery.
Keywords: Assay, Bioanalytical Testing, Data Science, Drug Development, Drug Discovery, Drug Target Identification, Genomics, Pre-Clinical, RNA Therapeutics, Toxicology/Safety, Transcriptomics
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
George Pilitsis, Director, Product, Ginkgo Datapoints
Ayla Ergun, Sr. Director, Computational Biology & AI, Ginkgo Datapoints
Kurt Cox, Senior Engineer, Ginkgo Datapoints
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-11-14
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|